Accretion Bio
Backed by Antler Australia · accretion.bio ↗
Accretion Bio is building a pipeline of drug programs for brain disease. It uses imaging that tracks single molecules moving inside living neurons in real time, at nanometre resolution. The aim is to show how brain disease begins and to produce data on how a drug works that conventional screens cannot reach.
Why it matters in Australia: Antler Australia has backed Accretion Bio since 2026.
Backed by
- Antler Australia first invested 2026 Antler Australia profile ↗
Similar companies
Andromeda
Where technology meets empathy – pioneering the future of human-robot interaction.
Everlab
Marc, Sam, Anshul and Steven are on a mission to help people live longer, healthier lives.
9 roles in Australia
Auggie
Auggie is the AI patient retention platform that turns dormant dental patient lists into recovered revenue.
Currus Biologics
Developing the next generation of CAR-T cell therapies to treat solid cancers.
indi
One connected system for child development care
Minikai
Your AI ally in disability and aged care.
The summary above was written with AI from the company's own site and its backers' listings, and checked by an editor. Backers, years and rounds are as each fund lists them. Open roles are read daily from the funds' jobs boards.